Reviewed by the Help Dementia Editorial Team — our editors review every article for accuracy against guidance from the National Institute on Aging, the Alzheimer’s Association, and peer-reviewed sources.
Brain scans sits at the center of this dementia and brain health question.
Brain scans remain essential to dementia diagnosis because they directly visualize structural and functional changes in the brain that occur with the disease. While doctors can assess memory and cognition through interviews and cognitive testing, only brain imaging reveals the actual pathological changes—whether it’s the protein accumulation of Alzheimer’s disease, the atrophy patterns of frontotemporal dementia, or the vascular damage from stroke-related dementia. A person experiencing memory loss might have multiple possible causes, but an MRI scan can show doctors whether their brain is shrinking in specific regions, whether they’ve had silent strokes, or whether fluid buildup exists where it shouldn’t, allowing a definitive diagnosis rather than an educated guess.
Brain imaging has become even more critical in recent years because of what we now know: dementia changes the brain years before anyone notices symptoms. Research has demonstrated that doctors can predict who will develop dementia up to five years before their first clinical diagnosis by examining MRI scans they already have on file. This means a brain scan isn’t just a confirmatory test for someone already struggling with memory—it’s a potential early warning system that could reshape how we approach brain health care.
Table of Contents
- Why Brain MRI Remains the First-Line Neuroimaging Tool
- Early Detection Through Advanced Brain Imaging
- Artificial Intelligence is Transforming Dementia Detection
- Choosing the Right Brain Imaging for Your Situation
- Where Blood Biomarkers Fit Alongside Brain Imaging
- Special Imaging Considerations for Specific Populations
- The Future of Brain Imaging in Dementia Care
- Conclusion
Why Brain MRI Remains the First-Line Neuroimaging Tool
The American Academy of Neurology, National Institute on Aging, and American College of Radiology all recommend brain MRI as the first neuroimaging choice when dementia is suspected. This isn’t just preference—it reflects decades of clinical evidence. MRI provides clear pictures of brain structure without radiation exposure, making it safer for repeated use and follow-up studies. For most patients presenting with memory concerns, an MRI will show whether their brain has the characteristic patterns of different dementia types: the widespread shrinkage of Alzheimer’s disease, the frontal and temporal lobe damage of frontotemporal dementia, the white matter changes of vascular dementia, or the normal pressure hydrocephalus that sometimes mimics dementia but is actually treatable. However, MRI has significant limitations that doctors must consider. The scan itself takes 30 to 60 minutes, requiring patients to stay very still in a loud, confined space—a challenge for anxious patients or those with claustrophobia.
It’s also expensive, often costing $1,000 to $3,000, and many insurance plans require pre-authorization. Some patients cannot undergo MRI at all due to metal implants like pacemakers or certain surgical hardware. For these reasons, not every person suspected of having dementia immediately receives an MRI; doctors typically order one after cognitive testing raises red flags. Recent technological advances are changing this picture. Researchers at University College London developed a new MRI technique that cuts scan time by roughly two-thirds while maintaining diagnostic accuracy equivalent to standard scans. If this technology becomes widely available, it could remove one of the biggest barriers to early MRI screening—the length and difficulty of the procedure itself.
Early Detection Through Advanced Brain Imaging
One of the most significant discoveries in dementia research is that brain imaging can now reveal disease changes long before symptoms appear. A 2025 study using machine learning algorithms showed that researchers could identify which patients would develop dementia up to five years before their first diagnosis by analyzing routine MRI data. The algorithm looked for subtle patterns in brain structure—minor volume loss, specific changes in white matter—that humans couldn’t reliably spot but that predicted future decline. This represents a fundamental shift in how we think about dementia: instead of diagnosing the disease after it has already affected someone’s thinking and memory, brain scans could identify vulnerable individuals years earlier, when interventions might have the most benefit. The challenge with early detection is knowing what to do with the information.
If a brain scan shows changes suggestive of future dementia, should patients be told? Should they start preventive medications or lifestyle changes? Current guidelines don’t yet fully address these questions, and many doctors remain cautious about ordering imaging specifically for screening purposes. Additionally, not everyone whose brain shows early dementia changes will necessarily develop symptoms in their lifetime—some people die of other causes before dementia becomes apparent. More research is underway to turn early detection into early intervention. Several studies are testing whether lifestyle modifications, cognitive training, or medications can slow or prevent the cognitive decline that brain imaging predicts. As these studies mature, the ability to see dementia changes on MRI years in advance could become one of the most powerful tools in dementia prevention.
Artificial Intelligence is Transforming Dementia Detection
In June 2025, Mayo Clinic researchers unveiled StateViewer, an artificial intelligence system that identifies nine different types of dementia—including Alzheimer’s disease, frontotemporal dementia, Lewy body dementia, and five others—with 88% accuracy using a single brain MRI scan. The system was trained on more than 3,600 brain scans from patients with confirmed diagnoses, allowing it to recognize patterns that distinguish one dementia type from another. Previously, accurately distinguishing between dementia subtypes often required multiple imaging tests, specialist consultations, and sometimes even months of clinical observation. StateViewer can do it with one scan. This is a remarkable advance, but it comes with important caveats. An AI system’s 88% accuracy means it gets about one in nine cases wrong—a significant error rate when the diagnosis determines treatment decisions for months or years.
AI algorithms also tend to perform best on patients from the same demographic backgrounds as their training data; someone with unusual brain anatomy or a rare presentation might be misclassified. Additionally, these tools exist in research settings so far; getting them into routine clinical practice requires FDA approval, clinician training, and integration into hospital systems—a process that typically takes years. Another emerging biomarker visible on advanced MRI is glymphatic system dysfunction. The glymphatic system is the brain’s drainage network, clearing out toxic proteins like amyloid-beta and tau that accumulate in Alzheimer’s disease. Recent research shows that clogged glymphatic drainage—visible on MRI—can be an early red flag for Alzheimer’s disease, often appearing years before cognitive symptoms emerge. This provides doctors another specific structural marker to track when assessing dementia risk.
Choosing the Right Brain Imaging for Your Situation
Not all brain imaging is the same, and the right choice depends on the clinical question being asked. MRI excels at showing brain structure—shrinkage, strokes, tumors—but it doesn’t show how active the brain tissue is. For that, doctors turn to PET imaging, specifically 18F-fluorodeoxyglucose (FDG) PET scans, which light up areas of active brain metabolism. FDG-PET has superior sensitivity and specificity for distinguishing Alzheimer’s disease from frontotemporal dementia and other subtypes, showing the characteristic metabolic patterns specific to each disease. The trade-off is significant: PET scans use radioactive tracers, expose patients to radiation, cost $3,000 to $6,000 or more, and aren’t available in every hospital. The most accurate approach combines both modalities.
Studies show that using PET and MRI together is more accurate for dementia detection than either imaging alone, because they provide complementary information—structure and function in one assessment. Some academic medical centers offer hybrid PET/MRI scans, where both images are acquired simultaneously, but this technology is expensive and not widely available outside major research institutions. For most patients, the practical approach is to start with MRI, and if the clinical picture remains uncertain after MRI and cognitive testing, to consider PET imaging at a specialized dementia center. A growing alternative is magnetoencephalography (MEG) imaging, which detects electrical activity in the brain. Recent research identified high-power transient beta wave activity (12-30 Hz oscillations) on MEG as an early biomarker for Alzheimer’s disease, offering a direct window into neuronal stress. MEG is non-invasive, requires no contrast agents, and provides real-time functional information. However, MEG remains primarily a research tool; it’s not yet widely used for routine dementia diagnosis, partly because brain electrical activity is complex and difficult to interpret standardly.
Where Blood Biomarkers Fit Alongside Brain Imaging
In the past five years, blood-based biomarkers have emerged as powerful tools that complement brain imaging. The most exciting recent advance is the discovery that blood tests measuring phosphorylated tau 217 (pTau217) can detect Alzheimer’s pathology 15 to 20 years before symptoms appear. During the preclinical phase, plasma pTau217 levels increase approximately 8.5% annually, providing a concrete biological marker of disease progression. Unlike brain scans, blood biomarkers are inexpensive (typically $100 to $500), widely accessible, and can be repeated easily to track changes over time. However, blood biomarkers and brain imaging are complementary, not interchangeable. A blood biomarker tells you whether amyloid or tau proteins are abnormal—evidence of pathology—but it doesn’t show brain structure, location of damage, or whether other diseases (like vascular damage or Lewy bodies) are also present.
A person with elevated plasma pTau217 might have asymptomatic Alzheimer’s pathology, or that pathology might never progress to cognitive symptoms in their lifetime. Only brain imaging can reveal the full picture: where the damage is located, how extensive it is, whether there’s brain shrinkage, and whether other pathologies are contributing. This is why current dementia diagnosis relies on both: imaging reveals structure and burden of disease; blood biomarkers reveal biology and sometimes earlier detection. The practical implication is that blood biomarkers enable more efficient screening before imaging. A doctor might use a blood biomarker first to identify high-risk patients, then proceed to brain imaging for those who test positive. This approach reduces unnecessary scanning while ensuring that those most likely to benefit from early intervention get imaging-based confirmation.
Special Imaging Considerations for Specific Populations
Dementia isn’t one disease, and different types sometimes require specialized imaging approaches. In suspected Lewy body dementia, dopamine transporter imaging (DaTscan) can show depletion of dopamine in the striatum, a finding specific to Lewy body disease that helps distinguish it from Alzheimer’s disease. Similarly, when frontotemporal dementia is suspected, PET imaging might target tau pathology (tau-PET) rather than glucose metabolism, because the regional pattern of tau accumulation in frontotemporal dementia is different from Alzheimer’s. Vascular dementia requires careful MRI assessment for the distribution and severity of small vessel disease and previous strokes.
Older patients present particular imaging challenges. Brain atrophy is normal with age, making it harder to distinguish pathological shrinkage from normal aging. However, the pattern and location of atrophy can still be diagnostic—Alzheimer’s preferentially affects the medial temporal lobes, while frontotemporal dementia affects the frontal and temporal poles. Patients on blood thinners or with recent falls require careful interpretation of brain imaging, because old microhemorrhages (small brain bleeds) are common and don’t always indicate a specific dementia type. Getting the diagnosis right in older patients often requires an experienced radiologist and neurologist working together to integrate imaging findings with the patient’s symptoms and test results.
The Future of Brain Imaging in Dementia Care
Brain imaging is evolving rapidly, with several promising developments on the horizon. Multi-modal imaging approaches that combine structural MRI, functional MRI (showing brain activity), PET imaging (showing pathology burden), and advanced tractography (visualizing brain connections) are becoming feasible in research settings. Machine learning algorithms trained on thousands of multimodal scans are increasingly able to predict not just whether dementia will develop, but also how quickly it will progress and which treatments are most likely to help—so-called precision medicine approaches to dementia.
As neuroimaging technology improves and becomes more accessible, the question shifts from “Do we need brain scans?” to “When should everyone get one?” Some researchers propose that brain MRI screening could become routine at age 60 or 65, similar to mammography for breast cancer, to identify people with early dementia pathology before symptoms appear. Others caution that such widespread screening could lead to unnecessary anxiety and inappropriate treatment of asymptomatic disease. What’s certain is that brain imaging will remain central to dementia diagnosis and research for the foreseeable future, increasingly supported by AI analysis, blood biomarkers, and personalized medicine approaches.
Conclusion
Brain scans are still important in dementia diagnosis because they directly reveal the structural and functional changes underlying cognitive decline, offer the possibility of detection years before symptoms appear, and increasingly work alongside artificial intelligence and blood biomarkers to provide precise diagnosis. While no single test can definitively diagnose dementia (the diagnosis integrates imaging, cognitive testing, blood work, and clinical history), brain imaging provides irreplaceable information about what is actually happening in the brain. For someone experiencing memory concerns, an MRI can determine whether changes are related to Alzheimer’s disease, vascular dementia, frontotemporal dementia, or normal aging—a distinction that shapes everything from prognosis to treatment options.
If you or a loved one is experiencing cognitive changes, discussing brain imaging with your doctor is an important step. Modern neuroimaging, combined with blood biomarkers and cognitive assessment, offers the best chance of early and accurate diagnosis, and with earlier diagnosis comes earlier opportunity for intervention. The goal is no longer just identifying dementia after it has already affected daily life—it’s catching the disease earlier, when preventive strategies and treatments may have the greatest impact.
You Might Also Like
- Why Digital Biomarkers Are Growing in Dementia Research
- Can Early Diagnosis Improve Dementia Outcomes?
- Why Dementia Tech Needs Privacy and Consent Safeguards
For more, see Alzheimer’s Association.
